"A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE."

Registry ID

MK-3475-061

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2017-02-21

Last update

2015-06-18

Conditions

• GASTRIC CANCER
• GASTROESOPHAGEAL JUNCTION CANCER
• ADENOCARCINOMA

Related clinical trials

• ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
• A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (CLARITY-GASTRIC 02)
• A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
• A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
• A RANDOMIZED, PHASE III STUDY OF RILVEGOSTOMIG IN COMBINATION WITH FLUOROPYRIMIDINE AND TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB, CHEMOTHERAPY, AND PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE GASTRIC CANCER (ARTEMIDE-GASTRIC01)
• A PHASE III MULTI-CENTER, OPEN-LABEL, SPONSOR-BLINDED, RANDOMIZED STUDY OF AZD0901 MONOTHERAPY COMPARED WITH INVESTIGATOR¿S CHOICE OF THERAPY IN SECOND- OR LATER-LINE ADULT PARTICIPANTS WITH ADVANCED/METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING CLAUDIN18.2

View on source registry